Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
After weeks of speculation, the embattled Canadian drug maker Valeant Pharmaceuticals International Inc. – which has been trying to...